BMS, AbbVie immuno-oncology med jumps on FDA fast track; Amgen, UCB tout Forteo-beating bone drug data;

> The FDA put Bristol-Myers Squibb ($BMY) and AbbVie's ($ABBV) immuno-oncology treatment for multiple myeloma, Empliciti (elotuzumab), on its priority review track. Release

> Amgen ($AMGN) and UCB said their osteoporosis treatment romosozumab topped Eli Lilly & Co.'s ($LLY) Forteo at increasing hip bone density in post-menopausal women at high risk of fracture. Release | More

> European regulators gave the green light to Novartis' ($NVS) first-in-class drug Revolade for patients with severe aplastic anemia. Release

> The FDA expanded approval for Merck & Co.'s ($MRK) chemotherapy-related nausea drug Emend for use in some children. Release

> Tesaro ($TSRO) won FDA approval for its first drug, Varubi, a treatment for chemo-related nausea and vomiting in adults. Release

> Allergan ($AGN) said the official FDA labeling on its anti-infective drug Teflaro was updated to support a shorter infusion time. Release

And Finally... Swiss authorities approved reimbursement of the Norgine liver drug Xifaxan. Release

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.